Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study

Fig. 3

Nomogram for survival prediction of hospitalized COVID-19 patients receiving azvudine in the Henan cohort. a LASSO coefficient profile of 40 features. b Tuning parameter (λ) selection in the LASSO model via fivefold cross-validation. c Nomogram to estimate 10-, 20-, and 30-day survival for COVID-19 patients receiving azvudine. The prediction performance of the LASSO model evaluated by ROC curves in the training set (d) and test set (e)

Back to article page